Kabra Drugs Ltd (524322) — FY26 Annual Report | 8 September 2026

Aanjaay Industries Limited (formerly Kabra Drugs Limited) filed its 2025-26 Annual Report with BSE on September 8, 2026, announcing the 37th Annual General Meeting on September 30, 2026, at Chennai. The report details a turnaround: revenue surged to ₹9,323.27 lakhs from ₹64.02 lakhs, profit after tax improved to ₹495.98 lakhs from a loss of ₹108.56 lakhs, and EPS rose to ₹2.09 from [amount not verified]Key changes include new independent director Moonam Kapoor, secretarial auditor Twinkle Agarwal, and CFO Pavanasam. No dividend was declared. Management highlights operational restructuring, strategic shift to trading, and positive cash flow trends. Risks include high trade receivables (₹7,077.60 lakhs) and regulatory compliance. The filing confirms no material changes in reserves or commitments.